Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion-metabolism positron emission tomography study

Nuclear Medicine Communications

Volumn 29, Issue 5, 2008, Pages 448-454

  Feola, Mauro ^a   Biggi, Alberto ^a   Chauvie, Stéphane ^a   Vado, Antonello ^a   Leonardi, Giovanni ^a   Rolfo, Fabrizio ^b   Ribichini, Flavio ^b  

^a Departments of Cardiovascular Disease   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Insulin resistance; Ischaemic myocardial dysfunction; Myocardial positron emission tomography; Non viable myocardium

Indexed keywords

ACETYLSALICYLIC ACID; AMMONIA N 13; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART MUSCLE SCAR; HOSPITAL ADMISSION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; MYOCARDIAL HIBERNATION; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; SCAR;

COMORBIDITY; FEMALE; HUMANS; INSULIN RESISTANCE; ITALY; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; MYOCARDIAL STUNNING; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 41949130373     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f5d2bc     Document Type: Article

References (31)

1. Marshall RC, Tillish JH, Phelps ME, Huang SC, Carson R, Henze E, Schelbert HR. Identification and differentiation of resting myocardial ischemia and infarction in men with positron computed tomography 18-F-labeled fluorodeoxyglucose and N-13-ammonia. Circulation 1983; 64:766-768.
2. Brunken R, Tillisch J, Schwaiger M, Child JS, Marshall R, Mandelkern H, et al. Regional perfusion, glucose metabolism and wall motion in chronic electrocardiographic Q-wave infarctions: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986; 73:951-963.
3. Tillish J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884-888.
4. Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989; 64:860-865.
5. Allman KC, Shaw L, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151-1158.
6. Haas F, Augustin N, Holper K, Wottke M, Haennel C, Nekolla S, et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomography findings. J Am Coll Cardiol 2000; 36:1927-1934.
7. Beanlands RSB, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40:1735-1743.
8. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AM, Kaul S, Laskey WK, et al. Standardised myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the Council of Clinical Cardiology of the American Heart Association. Circulation 2002; 105:539-542.
9. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 273:E214-E223.
10. Bax JJ, Visser FC, Poldermans D, van Lingen A, Elhendy A, Boersma E, Visser CA. Feasibility, safety and image quality of cardiac FDG studies during hyperinsulinaemic-euglycemic clamping. Eur J Nucl Med 2002; 29:452-457.
11. 18F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease and left ventricular dysfunction. J Nucl Med 2001; 42:1730-1736.
12. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997; 30:1451-1460.
13. Pagano D, Towned J, Littler W, Horton R, Camici P, Bonser R. Coronary artery bypass surgery as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg 1998; 115:791-799.
14. Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H, Schwaiger M. Preoperative positron emission tomography assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30:1693-1700.
15. Bax JJ, Visser FC, Poldermans D, Elhendy A, Cornel JH, Boersma E, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 2001; 104 (Suppl):I-314-I-318.
16. Desideri A, Cortigiani L, Christen AI, Coscarelli S, Gregari D, Zanco P, et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005; 46:1264-1269.
17. Rett K. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999; 1 (Suppl 1):S8-S16.
18. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
19. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome: a population based study. Diabetes Care 1998; 21:649-654.
20. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-957.
21. Pyorala M, Miettinen L, Pyorala K, Lasko M. Hyperinsulinemia predicts coronary artery disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policeman Study. Circulation 1998; 98:398-404.
22. Pyorala M, Miettinen L, Halonen P, Lasko M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary artery disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policeman Study. Arterioscler Thromb Vasc Biol 2000; 20:538-544.
23. Feola M, Ribichini F, Ferrero V, Procopio M, Magro G, Vado A, et al. Comparison of frequency of insulin resistance after coronary stenting in patients with type 2 diabetes mellitus with versus without coronary restenosis. Am J Cardiol 2004; 94:777-780.
24. Levantesi G, Macchia A, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46:277-283.
25. Surdaki A, Stochmal E, Szurkowsaka M, Bode-Boger SM, Martens-Lobenhoffer J, Stochmal A, et al. Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance. Metabolism 2007; 56:77-86.
26. Juhan-Vague I, Alessi MC, Vague P. Increased plasma activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34:457-462.
27. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex related differences in the Framingham Study. Circulation 2003; 107:448-454.
28. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, Camici PG. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction and coronary artery disease. J Am Coll Cardiol 2006; 48:2225-2231.
29. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary artery disease. A study with positron emission tomography. J Clin Invest 1996; 98:2094-2099.
30. Opie LH, Sack MN. Metabolic plasticity and promotion of cardiac protection in ischemia and ischemic preconditioning. J Mol Cell Cardiol 2002; 34:1077-1089.
31. Knuuti J, Schelbert HR, Bax JJ. The need of standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med 2002; 29:1257-1266.